Alemtuzumab receives Health Canada approval


Alemtuzumab, a monoclonal antibody that targets CD52 on T and B lymphocytes, has received approval in Canada for the treatment of adults aged 18-64 years with relapsing-remitting MS who have had an inadequate response to interferon-beta or other disease-modifying

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page